FDA approves first mRNA flu vaccine after reversing its own rejection
The Food and Drug Administration has approved the first messenger RNA-based vaccine for seasonal flu, after rejecting it earlier this year.
The Food and Drug Administration has granted approval for the first seasonal flu vaccine utilizing messenger RNA (mRNA) technology. This decision follows an earlier rejection of the vaccine by the same agency. The approval marks a significant advancement in influenza prevention.
- The FDA has approved the first mRNA-based vaccine for seasonal flu.
- This approval comes after the FDA had previously rejected the vaccine.
- The new vaccine uses messenger RNA technology.
Write a comment